StockData
Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc. (ALGS) shareholders

ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3043% below fair value
$1.66−0.44 (-20.95%)

Close on Nov 16, 2026Market cap $20.73MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
18.4%
2M of 12M shares
Institutional holders
31
5 new, 8 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Alyeska Fund GP, LLC
Joint filing with Alyeska Investment Group, L.P. (9.99%), Anand Parekh (9.99%)
530,0009.99%13G (passive)Mar 31, 2025
Sio Capital Management, LLC335,9375.46%13G (passive) amendmentDec 31, 2025
Lawrence M. Blatt316,2285.60%13D (active)Jun 16, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ALGSValueChange% of portfolio
Deep Track Capital, LP444,1103.56%$2.56M–0.04%
Alyeska Investment Group, L.P.412,0003.30%$2.38M–0.01%
Sio Capital Management, LLC327,2372.62%$1.89M–0.31%
Marshall Wace, Llp246,5791.97%$1.42M−20,5560.00%
Woodline Partners LP177,3621.42%$1.02M–0.00%
Vanguard Capital Management LLC175,5431.41%$1.01M−2,7190.00%
Baker Bros. Advisors LP83,0550.67%$479.23K–0.00%
Hhlr Advisors, Ltd.76,2470.61%$439.95K–0.05%
D. E. Shaw & Co., Inc.66,4630.53%$383.49K+55,4850.00%
UBS Group AG59,9860.48%$346.12K+22,9250.00%
Geode Capital Management, LLC47,1730.38%$272.32K−2,8020.00%
Jane Street Group, LLC32,4020.26%$186.96KNew0.00%
BlackRock, Inc.30,2920.24%$174.79K+17,2520.00%
Vanguard Fiduciary Trust Co28,6120.23%$165.09K+1750.00%
Dimensional Fund Advisors LP21,0440.17%$121.42KNew0.00%
Verition Fund Management LLC18,8870.15%$108.98K–0.00%
Trexquant Investment LP12,3390.10%$71.20KNew0.00%
Renaissance Technologies LLC10,8000.09%$62.32K−89,6500.00%
Rockefeller Capital Management L.P.10,0000.08%$57.70K–0.00%
Federation des caisses Desjardins du Quebec4,6500.04%$26.83K+3,7000.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026312M18.4%5 / 77 / 80M1M
Q1 2026343M22.2%6 / 89 / 91M0M
Q4 2025393M22.5%11 / 97 / 51M1M
Q3 2025333M21.2%5 / 117 / 90M0M
Q2 2025373M21.7%9 / 108 / 71M1M
Q1 2025353M26.4%11 / 99 / 82M1M
Q4 2024332M13.0%12 / 104 / 60M1M
Q3 2024272M13.5%27 / 00 / 02M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

15 funds held ALGS in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ALGSValue% of fundAs of
Vanguard Total Stock Market Index Fund128,7701.03%$743.00K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund46,7730.37%$269.88K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund24,8090.20%$141.41K0.00%May 31, 2026
iShares Micro-Cap ETF16,4280.13%$94.79K0.01%Jun 30, 2026
U.S. Micro Cap Portfolio8,3290.07%$35.23K0.00%Jul 31, 2026
Fidelity Total Market Index Fund7,5530.06%$43.05K0.00%May 31, 2026
Fidelity Series Total Market Index Fund6,1410.05%$35.00K0.00%May 31, 2026
U.S. Small Cap Portfolio3,5730.03%$15.11K0.00%Jul 31, 2026
Fidelity Nasdaq Composite Index Fund3,5690.03%$20.34K0.00%May 31, 2026
Strategic Advisers U.S. Total Stock Fund3,2000.03%$18.24K0.00%May 31, 2026
Dimensional U.S. Small Cap ETF2,8100.02%$11.89K0.00%Jul 31, 2026
U.S. Vector Equity Portfolio2,0930.02%$8.85K0.00%Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF1,8550.01%$7.85K0.00%Jul 31, 2026
Avantis U.S. Small Cap Equity ETF1,4270.01%$8.13K0.00%May 31, 2026
Dimensional US Sustainability Core 1 ETF1,1490.01%$4.86K0.00%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Lawrence BlattPresident and CEO, Director1,866,09214.94%Mar 11, 2026
Nikhil AnejaPrincipal Accounting Officer––Mar 11, 2026
Julian A. SymonsSee Remarks394,0643.16%Mar 11, 2026
Lesley Ann CalhounSee Remarks––Mar 11, 2026
Margarita ChavezDirector––Jun 29, 2026
James Paul ScopaDirector183,0831.47%Jun 29, 2026
Carole NuechterleinDirector11,025,94188.28%Jun 29, 2026
Heather PrestonDirector––Jun 29, 2026
Bridget A. MartellDirector––Jun 29, 2026
Peter HirthDirector59,5490.48%Jun 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Lawrence Blatt
Chief Executive Officer, Director
Oct 25, 2023Award+610,277$0.76$463.81K1,847,575
Carole Nuechterlein
Director, 10% owner
Oct 25, 2023Buy+7,933,601$0.76$6.03M11,025,941
James Paul Scopa
Director
Oct 25, 2023Award+183,083$0.76$139.14K183,083
Thomas Woiwode
Director
Jun 11, 2021Other+8,383––8,383
Thomas Woiwode
Director
Jun 11, 2021Other−9,719––0
Thomas Woiwode
Director
Jun 11, 2021Other+9,719––9,719
Thomas Woiwode
Director
Jun 11, 2021Other+2,226––4,452
Thomas Woiwode
Director
Jun 11, 2021Other−8,383––0
Thomas Woiwode
Director
Jun 11, 2021Other−485,979––1,457,937
Thomas Woiwode
Director
Apr 26, 2021Other−485,979––1,943,916
Thomas Woiwode
Director
Apr 26, 2021Other+9,720––9,720
Thomas Woiwode
Director
Apr 26, 2021Other−9,720––0
Thomas Woiwode
Director
Apr 26, 2021Other+8,385––8,385
Thomas Woiwode
Director
Apr 26, 2021Other−8,385––0
Thomas Woiwode
Director
Apr 26, 2021Other+2,226––2,226
Holdings A/S Novo
10% owner
Oct 20, 2020Buy+200,000$15.00$3.00M2,614,563
Holdings A/S Novo
10% owner
Oct 20, 2020Conversion+2,414,563––2,414,563
Biomedical Innovation Master Investors (Cayman) I. L.P. Wellington
10% owner
Oct 20, 2020Conversion+1,335,048––1,335,048
Biomedical Innovation Master Investors (Cayman) I. L.P. Wellington
10% owner
Oct 20, 2020Conversion+571,143––1,906,191
Thomas Woiwode
Director
Oct 20, 2020Conversion+198,485––662,444
Thomas Woiwode
Director
Oct 20, 2020Buy+200,000$15.00$3.00M862,444
Thomas Woiwode
Director
Oct 20, 2020Conversion+85,065––2,429,895
Thomas Woiwode
Director
Oct 20, 2020Conversion+2,145,991––2,145,991
Thomas Woiwode
Director
Oct 20, 2020Conversion+198,839––2,344,830
Thomas Woiwode
Director
Oct 20, 2020Conversion+463,959––463,959
Vivo Capital Surplus Fund VIII, L.P.
10% owner
Oct 20, 2020Conversion+260,380––260,380
Vivo Capital Surplus Fund VIII, L.P.
10% owner
Oct 20, 2020Conversion+1,885,611––1,885,611
Vivo Capital Surplus Fund VIII, L.P.
10% owner
Oct 20, 2020Buy+483,267$15.00$7.25M3,116,658
Vivo Capital Surplus Fund VIII, L.P.
10% owner
Oct 20, 2020Conversion+30,939––363,639
Vivo Capital Surplus Fund VIII, L.P.
10% owner
Oct 20, 2020Conversion+72,320––332,700
Vivo Capital Surplus Fund VIII, L.P.
10% owner
Oct 20, 2020Buy+66,733$15.00$1.00M430,372
Vivo Capital Surplus Fund VIII, L.P.
10% owner
Oct 20, 2020Conversion+224,054––2,633,391
Vivo Capital Surplus Fund VIII, L.P.
10% owner
Oct 20, 2020Conversion+523,726––2,409,337
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+1,437––18,355
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+21,724––236,347
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+1,437––18,355
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+3,359––16,918
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+3,359––16,918
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+50,781––214,623
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+13,559––13,559
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+13,559––13,559
Leonid Beigelman
President, Director
Oct 20, 2020Conversion+163,842––163,842
Versant Venture Capital VI, L.P.
10% owner
Oct 20, 2020Conversion+198,839––2,344,830
Versant Venture Capital VI, L.P.
10% owner
Oct 20, 2020Conversion+463,959––463,959
Versant Venture Capital VI, L.P.
10% owner
Oct 20, 2020Conversion+85,065––2,429,895
Versant Venture Capital VI, L.P.
10% owner
Oct 20, 2020Conversion+198,485––662,444
Versant Venture Capital VI, L.P.
10% owner
Oct 20, 2020Conversion+2,145,991––2,145,991
Versant Venture Capital VI, L.P.
10% owner
Oct 20, 2020Buy+200,000$15.00$3.00M862,444
Carole Nuechterlein
Director
Oct 20, 2020Conversion+662,799––2,808,790
Carole Nuechterlein
Director
Oct 20, 2020Conversion+283,550––3,092,340
Carole Nuechterlein
Director
Oct 20, 2020Conversion+2,145,991––2,145,991
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+41,016––41,016
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+50,712––91,728
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+13,671––13,671
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+13,671––13,671
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+122,601––122,601
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+3,394––17,065
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+1,452––18,517
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+3,394––17,065
Lawrence Blatt
Chief Executive Officer
Oct 20, 2020Conversion+21,695––113,423

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
5.42%
1M shares short
Days to cover
20.8
At 0M shares a day
Change since last report
-4.3%
From 1M shares
Short volume, 20 days
48.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aligos Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,624 shares on Sep 22, 2026 over the last 90 days.

See a number that looks wrong?